BiosyentTSXV:RX +0.86%100 ROA % is 16.76% as of Mar. 2026, which is 5% below its 10-year median of 17.65. GuruFocus rates TSXV:RX with a GF Score™ of 100/100 and a GF Value™ of C$16.11 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Biosyent ranks better than 95.31% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Biosyent's annualizedNet Income for the quarter that ended in Mar. 2026 was C$9.38 Mil.
Biosyent's average Total Assets over the quarter that ended in Mar. 2026 was C$55.97 Mil. Therefore, Biosyent's annualized ROA % for the quarter that ended in Mar. 2026 was 16.76%.
The historical rank and industry rank for Biosyent's ROA % or its related term are showing as below:
TSXV:RX'
s ROA % Range Over the Past 10 Years
Min: 11.76 Med: 17.65 Max: 25.46
Current: 18.37
During the past 13 years, Biosyent's highest ROA % was 25.46%. The lowest was 11.76%. And the median was 17.65%.
TSXV:RX's ROA % is ranked better than 95.31% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs TSXV:RX: 18.37
Biosyent (TSXV:RX) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Biosyent ROA % Related Terms
Biosyent ROA % Historical Data
* Premium members only.
The historical data trend for Biosyent's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's ROA % distribution charts can be found below:
* The bar in red indicates where Biosyent's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Biosyent (TSXV:RX) has a ROA % of 16.76% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Biosyent and its competitors. This is near median its historical median of 17.65. Over the past decade, Biosyent's ROA % has ranged from 11.76 to 25.46. According to the industry distribution chart, Biosyent ranks #47 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is Biosyent's ROA % too high?
Biosyent's current ROA % of 16.76% is near median its 10-year median of 17.65. Over the past 10 years, this metric has ranged from a low of 11.76 to a high of 25.46. The Drug Manufacturers industry median ROA % is 2.69. Biosyent's value of 16.76% is 523% above this industry median. Based on the distribution chart, Biosyent ranks #47 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biosyent has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #47 out of 1003 companies for ROA %. This places Biosyent in the top 5% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. Biosyent's value of 16.76% is 523% above this benchmark. Historically, Biosyent's own ROA % has ranged from 11.76 to 25.46 over the past decade. While the company's 10-year median is 17.65 vs. the industry median of 2.69, Biosyent has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current ROA % of 16.76% is 523% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current ROA % is 16.76%, which is near median its own 10-year median of 17.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (TSXV:RX) is currently considered Modestly Undervalued. The stock's GF Value™ is C$16.11, compared to a current price of C$14.05 — trading 12.8% below its estimated fair value. The current ROA % is 16.76%, which is near median its 10-year median of 17.65 and 523% above the Drug Manufacturers industry median of 2.69. Biosyent's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Biosyent (TSXV:RX), the current ROA % is 16.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (TSXV:RX) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of C$14.05 is trading 12.8% below its estimated GF Value™ of C$16.11.
GuruFocus considers Biosyent to be Modestly Undervalued.
Key valuation signals for TSXV:RX:
ROA %: 16.76% (near median its 10-year median of 17.65)
GF Value™: C$16.11 vs. price of C$14.05 (12.8% below fair value)
Industry Position: 523% above the Drug Manufacturers median (#47 of 1003)
No single metric tells the full story. See the TSXV:RX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
100GF Score
Get the complete analysis for TSXV:RX
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:RX has been successfully added to your 
